Biodistribution of 131I in mice is influenced by circadian variations

Andersson, Charlotte; Elvborn, Mikael; Spetz, Johan; Langen, Britta; Forssell-Aronsson, Eva

doi:10.1038/s41598-020-72180-7

Cited by 2 publications

(1 citation statement)

References 37 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significantly, one of the main driving forces is the so-called theranostic concept that combines the diagnostic use of one biomarker with a therapeutic option. Some studies have confirmed the value of combined radionuclide PET/CT in neuroendocrine tumors (3), prostate cancer (4), or hematological malignancies (5,6) for the evaluation of efficacy, metastasis, or recurrence monitoring, and some tumors could even be treated with radionuclide-labeled antibodies. Especially, thyroid treatment post-thyroidectomy is the classical protocol where sufficiently large activities of radionuclide 131I are given by mouth to the patient (7); it is still a unique method of cancer treatment (8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of mobile robots collecting vital signs and radiation dose rate for patients receiving Iodine-131 radiotherapy: A randomized clinical trial

Gao

Fan

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

ObjectivePatients receiving radionuclide 131I treatment expose radiation to others, and there was no clinical trial to verify the effectiveness and safety of mobile robots in radionuclide 131I isolation wards. The objective of this randomized clinical trial was to evaluate the effectiveness and safety of mobile robots in providing vital signs (body temperature and blood pressure) and radiation dose rate monitoring for patients receiving radionuclide therapy.MethodsAn open-label, multicenter, paired, randomized clinical trial was performed at three medical centers in Shanghai and Wuhan, China, from 1 April 2018 to 1 September 2018. A total of 72 participants were assigned to the group in which vital signs and radiation doses were both measured by mobile robots and conventional instruments. Intergroup consistency, completion rate, and first success rate were the primary effectiveness measures, and vital sign measurement results, the error rate of use, and subjective satisfaction were secondary indicators. Adverse events related to the robot were used to assess safety.ResultsOf the 72 randomized participants (median age, 39.5; 27 [37.5%] male participants), 72 (100.0%) completed the trial. The analysis sets of full analysis set, per-protocol set, and safety analysis set included 72 cases (32 cases in Center A, 16 cases in Center B, and 24 cases in Center C). The consistency, completion rate, and first success rate were 100% (P = 1.00), and the first success rates of vital signs and radiation dose rate were 91.7% (P = 1.000), 100.0% (P = 0.120), and 100.0% (P = 1.000). There was no significant difference in vital signs and radiation dose rate measurement results between the robot measurement group and the control group (P = 0.000, 0.044, and 0.023), and subjective satisfaction in the robot measurement group was 71/72 (98.6%), compared to 67/72 (93.1%) in the control group. For safety evaluation, there was no adverse event related to the mobile robot.ConclusionThe mobile robots have good effectiveness and safety in providing vital signs and radiation dose rate measurement services for patients treated with radionuclides.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of mobile robots collecting vital signs and radiation dose rate for patients receiving Iodine-131 radiotherapy: A randomized clinical trial

Gao

Fan

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

Recent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine

Soliman¹,

Alenezi²,

Alrushoud³

et al. 2022

Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy

View full text Add to dashboard Cite

Adequate understanding of radiopharmaceutical distribution in the body of the patient has both spatial and temporal characteristics and they are the key factor to consider when planning successful radio pharmaceutical therapy, because they are an integral part of the radiation dosimetry calculations of any proposed personalized treatment. In this chapter we will focus on radioiodine therapy for thyroid cancer patients since it is a widely known practice in clinical oncology. Factors affecting the radioiodine organs’ distribution will be examined in sufficient details using the available published research in the scientific literature. The literature will be reviewed extensively and summarized in this chapter. Another aim is to provide the medical practitioners with a quick reference guide to this clinically important area of expertise; often mastered by medical physicists with background in radiation physics, mathematics and medical imaging analysis. This chapter will cover recent advances in the area of radioiodine biodistribution modeling with applications in preclinical and clinical studies.

show abstract

Biodistribution of 131I in mice is influenced by circadian variations

Cited by 2 publications

References 37 publications

Effectiveness of mobile robots collecting vital signs and radiation dose rate for patients receiving Iodine-131 radiotherapy: A randomized clinical trial

Effectiveness of mobile robots collecting vital signs and radiation dose rate for patients receiving Iodine-131 radiotherapy: A randomized clinical trial

Recent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine

Contact Info

Product

Resources

About